Table 2 Pharmacokinetic parameters of curcumin in the plasma
| Cmax (ng/mL) | AUC0-1h (ng/mL) | AUC0-4h (ng/mL) | AUC0-8h (ng/mL) | R.A.2) |
| Curcumin |
| Male | 2.86±5.711) | 0.00±0.00 | 2.86±5.71 | 8.58±17.15 | |
| Female | 1.06±1.48 | 0.19±0.42 | 1.59±3.56 | 4.84±8.61 | |
| Total | 1.86±3.77 | 0.11±0.31 | 2.16±4.36 | 6.50±12.30 | |
| Theracurmin® CR-033P |
| Male | 31.39±13.21** | 6.25±10.24 | 63.20±28.09** | 105.47±35.59** | 22.1 |
| Female | 24.07±9.32*** | 8.35±7.36* | 55.95±32.15** | 102.97±25.94*** | 35.2 |
| Total | 28.14±11.60*** | 7.18±8.60* | 59.98±28.23*** | 104.36±29.79*** | 27.8 |
Values are presented as mean±standard deviation.
Relative absorption= Theracurmin® CR-033P/Curcumin powder based on AUC0-4h.
Asterisk indicates significant of difference between control and Theracurmin® CR-033P using Student t-test (*p<0.05, **p<0.01, ***p<0.001).